Medicare's GLP-1 Bridge Program: Expanding Access to Weight Loss Medications
Medicare is introducing the "GLP-1 Bridge Program" to provide coverage for select GLP-1 medications to eligible beneficiaries under Medicare Part D. This program, starting next month, is a departure from the usual Medicare policy of not covering drugs specifically for weight loss. The initiative will run until December 31, 2027, and aims to expand access to GLP-1 drugs for qualifying individuals.
The GLP-1 drugs covered under the program include certain medications prescribed for weight loss. To be eligible for the program, individuals must be 18 years or older and meet specific health criteria. Those with a BMI of 27 or higher may also qualify if they are at risk of prediabetes, heart attack, or peripheral artery disease. A centralized system will manage approvals, claims processing, and payments to pharmacies for the covered medications.
Under the program, eligible patients will have a fixed monthly copayment of $50 for the GLP-1 medications. This program offers a unique opportunity for Medicare Part D enrollees to access these weight loss medications, which are typically not covered by Medicare. The initiative aims to provide support for individuals who meet the health criteria and could benefit from GLP-1 drugs as part of their treatment plan.